Palatin Technologies (0KF3) Stock Overview
A biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
0KF3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Palatin Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.71 |
| 52 Week High | US$72.50 |
| 52 Week Low | US$3.67 |
| Beta | -0.20 |
| 1 Month Change | 326.31% |
| 3 Month Change | 222.96% |
| 1 Year Change | -35.55% |
| 3 Year Change | -82.12% |
| 5 Year Change | n/a |
| Change since IPO | -97.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0KF3 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 110.7% | -3.0% | -0.007% |
| 1Y | -35.6% | 16.0% | 15.7% |
Return vs Industry: 0KF3 underperformed the UK Biotechs industry which returned 16% over the past year.
Return vs Market: 0KF3 underperformed the UK Market which returned 15.7% over the past year.
Price Volatility
| 0KF3 volatility | |
|---|---|
| 0KF3 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.9% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0KF3's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0KF3's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 29 | Carl Spana | palatin.com |
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases.
Palatin Technologies, Inc. Fundamentals Summary
| 0KF3 fundamental statistics | |
|---|---|
| Market cap | US$47.18m |
| Earnings (TTM) | -US$4.81m |
| Revenue (TTM) | US$8.85m |
Is 0KF3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0KF3 income statement (TTM) | |
|---|---|
| Revenue | US$8.85m |
| Cost of Revenue | US$11.68m |
| Gross Profit | -US$2.83m |
| Other Expenses | US$1.97m |
| Earnings | -US$4.81m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.82 |
| Gross Margin | -32.02% |
| Net Profit Margin | -54.32% |
| Debt/Equity Ratio | 0% |
How did 0KF3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 03:18 |
| End of Day Share Price | 2025/12/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Palatin Technologies, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| John Newman | Canaccord Genuity |
| I-Eh Jen | Laidlaw & Company (UK) Ltd |